Novavax
NVAX
381 hedge funds and large institutions have $2.49B invested in Novavax in 2022 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 146 increasing their positions, 99 reducing their positions, and 109 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 99
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.3% less ownership
Funds ownership: 44.48% → 44.18% (-0.3%)
11% less funds holding
Funds holding: 429 → 381 (-48)
40% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 109
41% less call options, than puts
Call options by funds: $492M | Put options by funds: $830M
48% less capital invested
Capital invested by funds: $4.81B → $2.49B (-$2.32B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coatue Management
New York
|
+$78.8M |
| 2 |
Millennium Management
New York
|
+$54.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$53.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$43.2M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$125M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$82M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$51.8M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$33.6M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$33.1M |
NVAX Hedge Fund Activity: Q1 2022 in Review
381 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q1 2022, worth a combined $2.49B — down 48% from $4.81B a quarter earlier.
Sellers outnumbered buyers: 109 funds closed out of NVAX and 65 opened new positions — a net loss of 44 holders — while 99 trimmed existing stakes and 146 added.
The largest buyer was Coatue Management, opening a new position worth an estimated $78.8M. The largest seller was RA Capital Management, cutting an estimated $125M.
- 381 institutional investors held Novavax (NVAX) as of Q1 2022, down from 429 in Q4 2021.
- Funds reported $2.49B of Novavax stock for Q1 2022, down 48% quarter-over-quarter.
- 65 funds opened new Novavax positions in Q1 2022 and 109 closed out, a net change of -44 holders.
- The largest Novavax buyer in Q1 2022 was Coatue Management, an estimated $78.8M added.
- The largest Novavax seller in Q1 2022 was RA Capital Management, an estimated $125M sold.
Based on aggregated 13F filings for Q1 2022.